http://orcid.org/0000-0001-7146-4740
Figures
Abstract
Aim
We analyzed the cross-sectional and prospective relationships between the accumulation of advanced glycation end products (AGE), assessed by skin autofluorescence (AF) and frailty and its components.
Methods
A total of 423 participants of the Bordeaux sample of the Three-City study 75 years of age or older in 2009–2010 were included in the cross-sectional analysis. Among them, 255 initially non-frail participants were re-examined 4 years later. Skin AF (arbitrary units (AU)) was measured using the AGE Reader. Frailty was defined using Fried’s criteria. Associations were assessed with logistic regression models.
Results
Mean skin AF at baseline was 2.81 ±0.68 AU and 16.8% participants were frail. Adjusted for sociodemographic and health characteristics, skin AF was associated neither with prevalent frailty as a whole (Odds Ratio (OR) = 1.2; 95% Confidence Interval: 0.8–1.9) nor with any of its components. Among 255 non-frail participants, 32 became frail over 4 years. In multivariate analyses, skin AF was not associated with incident frailty as a whole (OR = 1.0; 0.5–2.0) but with a doubled risk of incident exhaustion (OR = 2.0; 1.2–3.6) and low energy expenditure (OR = 2.0; 1.1–3.7). No association was observed with other criteria.
Conclusion
In French older community-dwellers aged 75 years and over, the accumulation of AGEs evaluated by skin AF was not associated with prevalent or incident frailty but with the 4-year risk of exhaustion and low energy expenditure. Further studies with larger samples are needed to confirm our results.
Citation: Pilleron S, Rajaobelina K, Tabue Teguo M, Dartigues J-F, Helmer C, Delcourt C, et al. (2017) Accumulation of advanced glycation end products evaluated by skin autofluorescence and incident frailty in older adults from the Bordeaux Three-City cohort. PLoS ONE 12(10): e0186087. https://doi.org/10.1371/journal.pone.0186087
Editor: Tilman Grune, Institute of Nutrition, GERMANY
Received: July 13, 2017; Accepted: September 25, 2017; Published: October 17, 2017
Copyright: © 2017 Pilleron et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The data are available upon request because of the ancillary study policy of the 3C group. The 3C sudy have been reviewed and approved by the ethics committee of the Centre Hospitalo-Universitaire of Bordeaux. Moreover it has been submitted to the French National Committee for personal computer database, with strict rules regarding the transmission of data. The procedure to request transmission of data and materials is described in the website: http://www.three-city-study.com/ancillary-studies.php.
Funding: The Three-City Study is conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), Victor Segalen – Bordeaux2 University and the Sanofi-Synthélabo company. The Fondation pour la Recherche Médicale funded the preparation and beginning of the study. The 3C-Study is also sponsored by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, Ministry of Research-INSERM Program Cohortes et collections de données biologiques, the Fondation Plan Alzheimer (FCS 2009-2012), and the Caisse Nationale pour la Solidarité et l’Autonomie (CNSA). This work was supported by the European Union’s Seventh Framework Programme (FP7/2007-2013) FRAILOMIC Project (grant number 305483) to SP. Study sponsors played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Competing interests: C Féart received fees for conferences from Danone Research and Nutricia. The other authors declare no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Introduction
Advanced glycation end products (AGEs) are produced by the glycation of proteins, lipids, and nucleic acids that can cause widespread tissue and cellular damages [1]. AGEs accumulate during normal aging [1] but in an excessive way in diabetes [2] and in chronic kidney disease [3]. AGEs are involved in the phenomenon of metabolic memory that refers to the long-term effect of previous poor metabolic environment [4]. Their accumulation could have an important role in frailty [5] and their accumulation in the skeletal muscle tissue is suggested as one of the causes of the reduction of muscle and physical function with aging [6].
Frailty is a reversible state associated with higher risk of dependence, institutionalization, morbidity and mortality [7]. Prevalence of frailty in older community-dwelling adults varies dramatically from 4 to 59% according to the definition used [8].
A few studies investigated the relationship between circulating AGEs and frailty in older community-dwelling adults [9–11], but circulating AGEs fluctuate physiologically. Measurement of tissue-bound AGEs seems more suitable for AGEs assessment, notably in tissues with a slow turnover such as dermis [12]. Skin autofluorescence (skin AF) is a non-invasive marker of the accumulation of AGEs in long-lived proteins [13]. To date, a single cross-sectional study has shown that skin AF was independently associated with grip strength and leg extension power in adult men [14].
No studies have investigated the association between skin AF and frailty or its components in older adults yet. We therefore examined the cross-sectional and prospective relationship of the accumulation of AGEs assessed by skin AF with frailty in French older community-dwellers 75 years of age or older.
Materials and methods
Study population
We used data of the Bordeaux sample of the Three-City (3C) study, a multicenter population-based cohort of community-dwellers 65 years of age or older started in 1999–2000 that aimed at estimating the risk of dementia attributable to vascular factors. Details are described elsewhere [15]. All participants gave their written informed consent. Data were collected using standardized questionnaires at baseline and follow-ups (wave 1 in 2001–2002, wave 2 in 2003–2004, wave 3 in 2006–2007, wave 4 in 2009–2010, wave 5 in 2011–2012 and wave 6 in 2013–2014). The 3C study has been approved by the ethical committees of the Kremlin-Bicêtre University Hospital (Paris) and Sud-Mediterranée II. The present analysis is based on data of waves 4 and 6 since definition of frailty was strictly comparable.
Of 1,214 participants seen in wave 4 (hereinafter referred to as baseline), 457 had complementary examinations including skin AF measurement. Among them, 433 had data on frailty status at baseline. We excluded 10 participants with missing data for covariates, remaining 423 for the cross-sectional analysis.
Of these, we excluded 71 prevalent frail participants, 42 deceased, 41 who were not seen at wave 6 and 14 with insufficient data to identify frailty in wave 6, leaving 255 for the prospective analysis.
Skin autofluorescence (skin AF)
At baseline, skin AF expressed as arbitrary units (AU) has been measured in triplicate at the skin site on the inner forearm–body part easily accessible and little exposed to the sun—using the AGE Reader (DiagnOptics Technologies B.V., Groningen, Netherlands) at Bordeaux University hospital [13]. The average of the three values was used in the analysis. Skin AF measurement was validated against skin biopsies and values were correlated with glycated collagen, pentosidine and Nε-carboxymethyl-lysine (CML) levels in healthy individuals, but also in Type 2 and Type 1 diabetes patients [13].
Frailty
According to Fried’s definition, participants were frail if they met 3 or more criteria among the following 5 self-reported criteria [7]: (i) shrinking; (ii) exhaustion; (iii) weakness; (iv) slowness; (v) low energy expenditure.
We defined shrinking (i) as the self-reported recent unintentional loss of 3 kg or more. In case of missing data (n = 5), this criteria was considered as fulfilled if body mass index (BMI) was <21 kg/m2. Exhaustion (ii) was defined using two items of the Center for Epidemiologic Studies Depression Scale (CES-D) [16]. Respondents were considered as exhausted if they answered yes to at least one of the two following items: During the past week, “I felt that everything I did was an effort” and “I could not get going”. Weakness (iii) was defined using the weakest quintile stratified by body mass index (BMI) and sex of the handgrip strength. Slowness (iv) was ascertained using the slowest quintile stratified by height and sex of the 4-meter gait speed. Respondents unable to complete the respective physical performance tests were included as weak and as slow. Low energy expenditure (v) was defined as reporting no engagement in physical activities (strenuous leisure activities or sport).
Other data
Baseline sociodemographic information included age, sex and education level (in two classes: low education level defined as no schooling or no diploma versus higher level). Smoking status was evaluated in 1999–2001 and categorized in “non-smokers” and “ex- or current smokers”. Polymedication was defined as participants taking ≥5 drugs at least once a week during the last month. Global cognitive performance was assessed using the Mini-Mental State Examination (MMSE) [17]. Depressive symptomatology was defined as a CES-D score ≥23 for women and ≥17 for men [16,18]. Diabetes mellitus (mainly Type 2) was defined as current use of antidiabetic drugs and/or fasting plasma glucose ≥7 mmol/L [19]. Estimated glomerular filtration rate (eGFR) was estimated using the modification of diet in renal disease study equation [20]. Chronic kidney disease (CKD) was defined as eGFR < 60 mL/ min/1.73 m2 [20].
Data analysis
Univariate associations were tested using Student’t test or ANOVA for normally distributed quantitative variables (skin AF), Wilcoxon test for non-normally distributed variables (age and MMSE) and χ2 test or Fisher exact test for categorical variables.
The multivariate associations between skin AF, prevalent frailty and the 4-year risk of frailty were investigated using a logistic regression model adjusted for age, sex, education level, smoking status, polymedication, depressive symptomatology, MMSE, diabetes mellitus and CKD.
Separate multivariate models were run with each frailty component as outcome in participants who did not fulfill the analyzed frailty component at baseline.
In all models, skin AF, age and MMSE were kept as continuous variables since log-linearity assumption could not be rejected.
Statistical analyses were performed with SAS Statistical package release 9.3 (SAS institute Inc., Cary, NC, USA).
Results
Cross-sectional association
The sample consisted of 423 participants (63.4% females; median age = 81.9±6.0). Frailty status was statistically associated with higher age, lower MMSE, more depressive symptoms, and the presence of CKD (Table 1). Skin AF was higher in men, in ex- or current smokers, in polymedicated participants, in participants with diabetes mellitus, and in those with CKD (Table 2). Median skin AF did not differ statistically based on frailty status or its components (Table 3).
Multivariate analyses showed no statistically significant association with frailty or its components in model adjusted for sociodemographic, health covariates including diabetes mellitus and CKD (Table 4).
Prospective association
The sample consisted of 255 non-frail participants. Median age was 80.4 ±5.1 and 62% were females.
Over the 4-year follow-up, 32 participants (12.5%) became frail. Incident frailty was statistically associated with higher age and the presence of depressive symptomatology (Table 1).
In the total sample, mean skin AF was 2.75 ± 0.62 AU and no correlation with age was found (Table 2). Statistically higher mean skin AF values were observed in polymedicated participants (p = 0.006) and in participants with diabetes mellitus (p = 0.01).
Mean skin AF did not differ statistically based on frailty status but was statistically higher in participants who reported exhaustion (p = 0.001) and low energy expenditure (p = 0.022) 4 years later (Table 3).
The multivariate analysis revealed no statistically significant association between skin AF and the 4-year risk of frailty (OR = 1.0; 95% Confidence Interval (CI): 0.5–1.9 –Table 4)). However, each 1-unit increase of skin AF doubled the risk of exhaustion (OR = 2.2; 95%CI: 1.2–3.7) and of low energy expenditure (OR = 1.9; 95%CI: 1.1–3.4).
Discussion
For the first time, this study investigated the association between a non-invasive measurement of AGEs accumulation and the risk of frailty and its components in French older community-dwellers. Our findings revealed no association between skin AF and prevalent or incident frailty but with incident exhaustion and incident low energy expenditure.
Previous studies in older community-dwellers were based on circulating AGEs. In 559 moderately to severely disabled women 65 years of age or older from the Women’s Health and Aging Study I, elevated serum Nε-carboxymethyl-lysine (CML) was associated with poor grip strength [9]. In 944 participants 65 years of age or older from the InCHIANTI cohort, participants in the highest quartile of plasma CML had greater odds of slow walking speed [21]. In the Cardiovascular Health Study, odds of frailty increased with higher serum CML concentrations in men but the strength of the association was attenuated by adjustment for cognitive status, kidney function, and arthritis [11]. Direct comparisons with our findings are difficult notably because AGEs measurements’ methods are different.
The lack of association between skin AF and prevalent or incident frailty was surprising at first sight. However, several hypotheses could explain this negative finding. First, low sample size limited statistical power. Secondly, skin AF was described by a linear increase with age but this observation was restricted to subjects under the age of 70 [22]. Beyond this age, skin AF threshold may somehow be reached (i.e. illustrating a plateau effect) making our very old sample (81 years old on average) homogenous regarding skin AF. Moreover, we found no correlation between age and skin AF in both samples (r = 0.01; p = 0.77 in cross-sectional analysis sample and r = -0.02; p = 0.74 in prospective analysis sample). Lastly, a survival effect may be a third explanation. Indeed, people who reach the age 75 are somewhat survivors and frail individuals or those with higher skin AF may have died before reaching the age of 75.
Elevated skin AF values were associated with an increased 4 year-risk of exhaustion but not with prevalent exhaustion. This is congruent with existing literature. In the Fried’s conceptualization of frailty, subclinical diseases may play an etiologic role in frailty [23]. Exhaustion was thought to precede myocardial infarction and predicts severity of coronary artery diseases [24,25]. Skin AF is associated with atherosclerosis [26], elevated in stable coronary arteries diseases [27,28] and correlated with carotid intima media thickness [29]. Our findings also revealed an association with incident low energy expenditure and once again not with prevalent low energy expenditure. No observational studies have reported results about AGEs and physical activity so far. However, physical activity induced a statistically significant reduction of serum AGEs in interventional studies [30,31].
The lack of cross-sectional association but the existence of prospective association with exhaustion and low energy expenditure suggest that accumulation of AGEs is not a marker but a predictor of these two criteria whatever the initial frailty status.
Surprisingly, we found no association between skin AF and low grip strength or low gait speed while some arguments in literature were in favor of such an association. Elevated AGEs was associated with severe walking disability [32], and slow gait speed [21] and AGEs accumulate in skeletal muscle with aging in rats [33]. Skin AF was associated with low skeletal muscle index among middle-aged and older Japanese [34]. No evident hypothesis can explain the lack of association in our study. This warrants further investigations.
Our study has several limitations to keep in mind when interpreting our findings. First, fluorescence of non-AGEs tissue components could be detected, whereas non-fluorescent AGEs were not measured. However, validation studies have shown a good correlation between skin AF level and fluorescent and non-fluorescent AGEs from skin biopsies [13]. Secondly, our sample size is small leading to a limited statistical power, which could prevent detecting some additional significant associations. Low sample size precludes testing interaction with sex while some studies suggested more deleterious effect of AGE in women [35] and some other showed that higher circulating CML level was associated with frailty only in older men [11]. Lastly, each time we are interested in elderly people, we have to face to a probable selection bias due to survival effect. It was shown that older adults with elevated serum AGEs were at an increased risk of mortality [10]. This could lead to underestimation of observed association. However, the prevalence of frailty in our cross-sectional sample is close to frailty prevalence (17.8% (95% CI: 14.8–20.8)) observed in a representative sample of individuals aged 75 years old or older from the Bordeaux Three-City [36].
The strengths of our study are the use of cross-sectional and prospective and population-based design, the use of a validated non-invasive measurement of AGEs [13] and adjustment for major confounders, notably diabetes mellitus, CKD and cognitive performances.
In conclusion, this population-based study in community-dwellers aged 75 years or over suggested that the accumulation of AGEs is neither marker nor predictor of the occurrence of frailty as a whole 4 years later, but it is predictor of some of its component. These findings need to be confirmed by further studies with larger sample size and younger participants.
References
- 1. Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci 2010;65:963–75. pmid:20478906
- 2. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands J- L, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008;7:29. pmid:18840258
- 3. Koyama H, Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur J Clin Invest 2010;40:623–35. pmid:20497213
- 4. Rajaobelina K, Cougnard-Gregoire A, Delcourt C, Gin H, Barberger-Gateau P, Rigalleau V. Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population. J Gerontol A Biol Sci Med Sci 2015;70:841–6. pmid:25589479
- 5. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013;381:752–62. pmid:23395245
- 6. Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol 2007;103:2068–76. pmid:17901242
- 7. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–56. pmid:11253156
- 8. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc 2012;60:1487–92. pmid:22881367
- 9. Dalal M, Ferrucci L, Sun K, Beck J, Fried LP, Semba RD. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. J Gerontol A Biol Sci Med Sci 2009;64:132–7. pmid:19182228
- 10. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 2009;57:1874–80. pmid:19682127
- 11. Whitson HE, Arnold AM, Yee LM, Mukamal KJ, Kizer JR, Djousse L, et al. Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 2014;69:710–6. pmid:24127427
- 12. Stirban A, Nandrean S, Negrean M, Koschinsky T, Tschoepe D. Skin autofluorescence increases postprandially in human subjects. Diabetes Technol Ther 2008;10:200–5. pmid:18473694
- 13. Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324–30. pmid:15243705
- 14. Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, et al. Skin advanced glycation end product accumulation and muscle strength among adult men. Eur J Appl Physiol 2011;111:1545–52. pmid:21188413
- 15. 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology 2003;22:316–25. pmid:14598854
- 16. Radloff LS. The CES-D scale: A self report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–401.
- 17. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98. pmid:1202204
- 18. Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’autoévaluation. Psychiatr Psychobiol 1989;4:163–6.
- 19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–53. pmid:9686693
- 20. Levey AS, de Jong PE, Coresh J, El Nahas M, Asto BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17–28. pmid:21150873
- 21. Semba RD, Bandinelli S, Sun K, Egan JM, Carlson OD, Varadhan R, et al. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study. Eur J Appl Physiol 2010;108:191–5. pmid:19756703
- 22. Koetsier M, Lutgers HL, de Jonge C, de Jonge C, Lings TP, Smit AJ, Graaff R. Reference values of skin autofluorescence. Diabetes Technol Ther 2010;12:399–403. pmid:20388050
- 23. Newman AB, Gottdiener JS, Mcburnie MA, Hirsch CH, Kop WJ, Tracy R, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci 2001;56:M158–66. pmid:11253157
- 24. Kop WJ, Appels AP, Mendes de Leon CF, Bär FW. The relationship between severity of coronary artery disease and vital exhaustion. J Psychosom Res 1996;40:397–405. pmid:8736420
- 25. Kop WJ, Appels AP, Mendes de Leon CF, de Swart HB, Bär FW. Vital exhaustion predicts new cardiac events after successful coronary angioplasty. Psychosom Med 1994;56:281–7. pmid:7972608
- 26. Den Dekker MAM, Zwiers M, van den Heuvel ER, de Vos LC, Smit AJ, Zeebregts CJ, et al. Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis. PloS One 2013;8:e83084. pmid:24376641
- 27. Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J 2009;17:162–8. pmid:19421362
- 28. Mulder DJ, van Haelst PL, Gross S, de Leeuw K, Bijzet J, Graaff R, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2008;197:217–23. pmid:17499742
- 29. Lutgers HL, Graaff R, de Vries R, Smit AJ, Dullaart RPF. Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest 2010;40:812–7. pmid:20597962
- 30. Yoshikawa T, Miyazaki A, Fujimoto S. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females. Med Sci Monit 2009;15:PH65–73. pmid:19478714
- 31. Goon JA, Aini AHN, Musalmah M, Anum MYY, Nazaimoon WMW, Ngah WZW. Effect of Tai Chi exercise on DNA damage, antioxidant enzymes, and oxidative stress in middle-age adults. J Phys Act Health 2009;6:43–54. pmid:19211957
- 32. Sun K, Semba RD, Fried LP, Schaumberg DA, Ferrucci L, Varadhan R. Elevated Serum Carboxymethyl-Lysine, an Advanced Glycation End Product, Predicts Severe Walking Disability in Older Women: The Women’s Health and Aging Study I. J Aging Res 2012;2012:586385. pmid:22973514
- 33. Snow LM, Fugere NA, Thompson LV. Advanced glycation end-product accumulation and associated protein modification in type II skeletal muscle with aging. J Gerontol A Biol Sci Med Sci 2007;62:1204–10. pmid:18000139
- 34. Kato M, Kubo A, Sugioka Y, Mitsui R, Fukuhara N, Nihei F et al. Relationship between advanced glycation end-product accumulation and low skeletal muscle mass in Japanese men and women. Geriatr Gerontol Int. April 2016. pmid:27119258
- 35. Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Hanssen KF, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007;50:1409–17. pmid:17479244
- 36. Tabue-Teguo M, Grasset L, Avila-Funes JA, Genuer R, Proust-Lima C, Péres K, et al. Prevalence and Co-Occurrence of Geriatric Syndromes in People Aged 75 Years and Older in France: Results From the Bordeaux Three-city Study. J Gerontol A Biol Sci Med Sci 2017. pmid:28541397